
    
      Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of S-1 (FT,
      gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 mg/body/day
      according to body surface area (BSA): BSA <1.25 m2, 80 mg/day; BSA >1.25 m2 but <1.5 m2, 100
      mg/day; and BSA >1.5 m2, 120 mg/day. S-1 was administered orally, twice daily after meals,
      starting within 4 weeks after surgery.
    
  